Pfizer will provide adequate COVID-19 treatment Paxlovid to the UK

Pfizer’s oral antiviral drug candidate Paxlovid is an investigational SARS-CoV-2 protease inhibitor that can treat COVID-19 in the early stage of COVID-19infection

Pfizer has announced an agreement with the British government to provide an additional 2.

Paxlovid is an investigational SARS-CoV-2 protease inhibitor antiviral therapy, which can be administered orally

Nirmatrelvir is designed to block the activity of the SARS-CoV-2 3CL protease, which is an enzyme required for coronavirus replication

If authorized, Paxlovid will be administered at a dose of 300 mg (two 150 mg tablets) and one 100 mg ritonavir, twice a day for five days

Albert Bourla, Chairman and CEO of Pfizer, commented: “The final data from our Phase 2/3 trial in high-risk participants confirms that Paxlovid has the ability to reduce the risk of hospitalization by nearly 90% compared to placebo.

In this study, trial participants were randomized 1:1, half of them received Paxlovid, and the other half received a placebo every 12 hours for five days

Original source:

https:// href="https://" target="_blank" rel="noopener">https:// https://